BIOPOR Bioporto A/S

BioPorto A/S - Annual General Meeting

BioPorto A/S - Annual General Meeting

April 14, 2020

Announcement no. 9

BioPorto A/S - Annual General Meeting

Today, BioPorto A/S held its Annual General Meeting during which the report on the Company’s activities was reviewed and the 2019 Annual Report was adopted. The proposed profit/loss allocation was also adopted and discharge of liability was granted to the Board of Directors and the Executive Management. Finally, the remuneration for the Board of Directors was approved.

Thomas Magnussen, Torben A. Nielsen, Kirsten Aarup Drejer, Christopher Lindop and Michael S. Singer were re-elected as members of the Board of Directors. Immediately following the Annual General Meeting, the Board of Directors elected Thomas Magnussen as its Chairman and Torben A. Nielsen as its Vice Chairman. 

The proposals from the Board of Directors under item 6 of the agenda were all adopted, and included: a) Amending the Articles of Association regarding shareholders’ notification of attendance for a general meeting, b) Amending the standard agenda for the Annual General Meeting in Article 8 in the Articles of Association, c) Renewing the authorization to issue warrants for up to DKK 2,500,000 following decision by the Board of Directors to amend its original proposal of up to DKK 6,600,000 shares, d) Approving the Company’s revised Remuneration Policy and e) Authorization to the Chairman of the general meeting.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

Hellerup, April 14, 2020

BioPorto A/S

The Board of Directors

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
14/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

Fortsat fremgang på vigtige strategiske milepæle i første kvartal af 2...

Fortsat fremgang på vigtige strategiske milepæle i første kvartal af 2025. Den samlede omsætning er i overensstemmelse med forventningerne, og guidance for 2025 fastholdes. 8. maj 2025Meddelelse nr. 15                                                                          Fortsat fremgang på vigtige strategiske milepæle i første kvartal af 2025. Den samlede omsætning er i overensstemmelse med forventningerne, og guidance for 2025 fastholdes. Delårsresultat og en forretningsstatus for første kvartal 2025 København, Danmark, 8. maj 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto eller S...

 PRESS RELEASE

Continued progress on key strategic milestones in Q1 2025. Total reven...

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. May 8, 2025Announcement no. 15                                                                          Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first quarter of fiscal 2025 Copenhagen, Denmark, May 8, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced interim financial resul...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 28. april 2025Meddelelse nr. 14                                                                          Tildeling af Warrants København, Danmark, den 28. april 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag implementeret beslutningen fra den ordinære generalforsamling afholdt den 11. april 2025 om at udstede i alt 1.700.000 warrants som en del af vederlaget til medlemmerne af Selskabets bestyrelse. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1.50 kr. pr. a...

 PRESS RELEASE

Grant of Warrants

Grant of Warrants April 28, 2025Announcement no. 14                                                                          Grant of Warrants Copenhagen, Denmark, April 28, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today implemented the resolution of the annual general meeting held on April 11, 2025 to issue a total of 1,700,000 warrants as part of the remuneration to members of the Board of Directors of the Company. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price...

 PRESS RELEASE

Ledende medarbejderes transaktioner

Ledende medarbejderes transaktioner 25. april 2025Meddelelse nr. 13                                                                          Ledende medarbejderes transaktioner I forbindelse med gennemførelsen af BioPorto A/S' rettede emission, som beskrevet i selskabsmeddelelse nr. 12, har BioPorto A/S i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget indberetning af nedenstående transaktioner vedrørende aktier i BioPorto A/S foretaget af personer med ledelsesansvar i BioPorto A/S og/eller nærtstående til disse. 1 Nærmere oplysninger om personen med ledelsesansvar/persone...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch